NCT00632840|CompletedPhase 4
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome
Loading search results
Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome
Sponsor study identifier
interventional
11
0 countries
N/A
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2002
Actual (reported)Study Completion
December 2007
Actual (reported)The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
December 2002
Actual (reported)December 2007
Actual (reported)February 20, 2008
Actual (reported)March 11, 2008
Actual (reported)VLDL-apoC-III transport rate
5 weeks
placebo group
Fenofibrate
Atorvastatin
atorvastatin (40mg/day) fenofibrate (200mg/day)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Atorvastatin and fenofibrate
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordChan DC, Watts GF, Ooi EM, Rye KA, Ji J, Johnson AG, Barrett PH. Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care. 2009 Nov;32(11):2111-3. doi: 10.2337/dc09-0519. Epub 2009 Aug 3.
Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009 Mar;94(3):989-97. doi: 10.1210/jc.2008-1457. Epub 2008 Dec 30.
Dick C Chan, PhD
The University of Western Australia
11 participants (actual enrollment reported by the registry).
First Submitted
February 20, 2008
First Posted
March 11, 2008
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
Contact the study team to confirm eligibility.
Primary Completion
December 2002
Actual (reported)Study Completion
December 2007
Actual (reported)Last Updated
March 11, 2008
Record last verified: 2008-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: